milrinone has been researched along with Hypotension in 34 studies
Hypotension: Abnormally low BLOOD PRESSURE that can result in inadequate blood flow to the brain and other vital organs. Common symptom is DIZZINESS but greater negative impacts on the body occur when there is prolonged depravation of oxygen and nutrients.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To determine the effect of milrinone on induced hypotension during spinal surgery in elderly patients." | 9.19 | The effect of milrinone on induced hypotension in elderly patients during spinal surgery: a randomized controlled trial. ( Hwang, W; Kim, E, 2014) |
| " We hypothesized that vasopressin could recover hypotension induced by milrinone with less effect on pulmonary vascular resistance (PVR) compared to norepinephrine." | 9.12 | Comparative hemodynamic effects of vasopressin and norepinephrine after milrinone-induced hypotension in off-pump coronary artery bypass surgical patients. ( Bahk, JH; Choi, JY; Jeon, Y; Kim, CS; Lim, YJ; Ryu, JH; Yoon, SZ, 2006) |
| "Hypotension is an adverse event that may be related to systemic exposure of milrinone; however, the true exposure-safety relationship is unknown." | 8.12 | The relationship between simulated milrinone exposure and hypotension in children. ( Balevic, SJ; Cohen-Wolkowiez, M; Commander, SJ; Gonzalez, D; Hornik, CP; Kumar, KR; Spears, T; Zimmerman, KO, 2022) |
| " Postoperatively, the patient had persistent sinus tachycardia that was initially unsuccessfully treated with metoprolol." | 7.70 | Treatment of milrinone-associated tachycardia with beta-blockers. ( Alhashemi, JA; Hooper, J, 1998) |
| "Vasopressin at very low doses appears to be an effective vasopressor for milrinone-induced hypotension." | 7.70 | Vasopressin as an alternative to norepinephrine in the treatment of milrinone-induced hypotension. ( Chen, J; Cullinane, S; Gold, JA; Landry, DW; Oliver, JA; Oz, MC, 2000) |
| "The use of phosphodiesterase inhibitors such as milrinone in the treatment of severe heart failure is frequently restricted because they cause vasodilation and hypotension." | 7.70 | Vasopressin in the treatment of milrinone-induced hypotension in severe heart failure. ( Chen, J; Cullinane, S; Gold, J; Landry, DW; Oliver, JA; Oz, MC; Seo, S, 2000) |
| " Patients were maintained on milrinone therapy for as long as 8 weeks and demonstrated a low incidence of adverse cardiac (7%) or noncardiac (4%) events." | 6.68 | Safety and clinical utility of long-term intravenous milrinone in advanced heart failure. ( Kapoor, C; Mehra, MR; Smart, FW; Stapleton, DD; Ventura, HO; Zimmerman, D, 1997) |
| "Milrinone is a phosphodiesterase type III inhibitor with positive inotropic and vasodilatory effects." | 5.31 | Acute renal failure secondary to milrinone in a patient with cardiac amyloidosis. ( Ewald, G; Mindel, G; Saab, G; Vijayan, A, 2002) |
| "To determine the effect of milrinone on induced hypotension during spinal surgery in elderly patients." | 5.19 | The effect of milrinone on induced hypotension in elderly patients during spinal surgery: a randomized controlled trial. ( Hwang, W; Kim, E, 2014) |
| " We hypothesized that vasopressin could recover hypotension induced by milrinone with less effect on pulmonary vascular resistance (PVR) compared to norepinephrine." | 5.12 | Comparative hemodynamic effects of vasopressin and norepinephrine after milrinone-induced hypotension in off-pump coronary artery bypass surgical patients. ( Bahk, JH; Choi, JY; Jeon, Y; Kim, CS; Lim, YJ; Ryu, JH; Yoon, SZ, 2006) |
| "Hypotension is an adverse event that may be related to systemic exposure of milrinone; however, the true exposure-safety relationship is unknown." | 4.12 | The relationship between simulated milrinone exposure and hypotension in children. ( Balevic, SJ; Cohen-Wolkowiez, M; Commander, SJ; Gonzalez, D; Hornik, CP; Kumar, KR; Spears, T; Zimmerman, KO, 2022) |
| "Population pharmacokinetic modeling and simulations suggest a slow loading dose followed by maintenance infusion to reach therapeutic milrinone plasma concentrations within the timeframe of the postligation cardiac syndrome." | 3.91 | Population Pharmacokinetics and Dosing of Milrinone After Patent Ductus Arteriosus Ligation in Preterm Infants. ( Hallik, M; Ilmoja, ML; Jalas, T; Kipper, K; Metsvaht, T; Raidmäe, M; Standing, JF; Starkopf, J; Takkis, K; Tasa, T; Uibo, K; Veigure, R, 2019) |
| " Postoperatively, the patient had persistent sinus tachycardia that was initially unsuccessfully treated with metoprolol." | 3.70 | Treatment of milrinone-associated tachycardia with beta-blockers. ( Alhashemi, JA; Hooper, J, 1998) |
| "Vasopressin at very low doses appears to be an effective vasopressor for milrinone-induced hypotension." | 3.70 | Vasopressin as an alternative to norepinephrine in the treatment of milrinone-induced hypotension. ( Chen, J; Cullinane, S; Gold, JA; Landry, DW; Oliver, JA; Oz, MC, 2000) |
| "The use of phosphodiesterase inhibitors such as milrinone in the treatment of severe heart failure is frequently restricted because they cause vasodilation and hypotension." | 3.70 | Vasopressin in the treatment of milrinone-induced hypotension in severe heart failure. ( Chen, J; Cullinane, S; Gold, J; Landry, DW; Oliver, JA; Oz, MC; Seo, S, 2000) |
| "Milrinone was associated with a higher incidence of sinus bradycardia (D = 2%, M = 13%; p < 0." | 2.70 | Comparison of the hemodynamic effects of milrinone with dobutamine in patients after cardiac surgery. ( Feneck, RO; Oduro-Dominah, A; Sherry, KM; Withington, PS, 2001) |
| " Patients were maintained on milrinone therapy for as long as 8 weeks and demonstrated a low incidence of adverse cardiac (7%) or noncardiac (4%) events." | 2.68 | Safety and clinical utility of long-term intravenous milrinone in advanced heart failure. ( Kapoor, C; Mehra, MR; Smart, FW; Stapleton, DD; Ventura, HO; Zimmerman, D, 1997) |
| "Milrinone has been suggested as a possible first-line therapy for preterm neonates to prevent postligation cardiac syndrome (PLCS) through decreasing systemic vascular resistance and increasing cardiac contractility." | 1.46 | Dosing of Milrinone in Preterm Neonates to Prevent Postligation Cardiac Syndrome: Simulation Study Suggests Need for Bolus Infusion. ( Hallik, M; Metsvaht, T; Starkopf, J; Tasa, T, 2017) |
| "Hypotension is a common problem in neonates with complex underlying pathophysiology." | 1.46 | Management of Neonatal Hypotension. ( Kalish, BT, 2017) |
| " We identified adverse events (AEs) during milrinone exposure." | 1.42 | Safety of milrinone use in neonatal intensive care units. ( Brian Smith, P; Clark, RH; Hornik, CP; McHutchison, K; Raman, SR; Samiee-Zafarghandy, S; van den Anker, JN, 2015) |
| "The echocardiographic presence of mild aortic regurgitation combined with left ventricular hypocontractility in a structurally normal heart should alert the physician to the presence of underlying hypertension." | 1.39 | Neonatal circulatory failure due to acute hypertensive crisis: clinical and echocardiographic clues. ( Allegaert, K; Brown, S; Cools, B; Eyskens, B; Gewillig, M; Heying, R; Levtchenko, E; Louw, J; Smits, A; Thewissen, L, 2013) |
| " Beta-blocker dosages were titrated, and three patients achieved the target beta-blocker dosage established for stage A-C heart failure." | 1.34 | Tolerability of beta-blockers in outpatients with refractory heart failure who were receiving continuous milrinone. ( Earl, GL; Fitzpatrick, JM; Narula, J; Verbos-Kazanas, MA, 2007) |
| "Milrinone is a phosphodiesterase type III inhibitor with positive inotropic and vasodilatory effects." | 1.31 | Acute renal failure secondary to milrinone in a patient with cardiac amyloidosis. ( Ewald, G; Mindel, G; Saab, G; Vijayan, A, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (11.76) | 18.2507 |
| 2000's | 14 (41.18) | 29.6817 |
| 2010's | 14 (41.18) | 24.3611 |
| 2020's | 2 (5.88) | 2.80 |
| Authors | Studies |
|---|---|
| Phad, N | 1 |
| de Waal, K | 1 |
| Commander, SJ | 1 |
| Gonzalez, D | 1 |
| Kumar, KR | 1 |
| Spears, T | 1 |
| Cohen-Wolkowiez, M | 1 |
| Zimmerman, KO | 1 |
| Balevic, SJ | 1 |
| Hornik, CP | 2 |
| Elhassan, A | 1 |
| Essandoh, M | 1 |
| Hallik, M | 2 |
| Ilmoja, ML | 1 |
| Tasa, T | 2 |
| Standing, JF | 1 |
| Takkis, K | 1 |
| Veigure, R | 1 |
| Kipper, K | 1 |
| Jalas, T | 1 |
| Raidmäe, M | 1 |
| Uibo, K | 1 |
| Starkopf, J | 2 |
| Metsvaht, T | 2 |
| Dempsey, E | 1 |
| Rabe, H | 1 |
| Qin, H | 1 |
| Jiang, W | 1 |
| EL-Khuffash, A | 1 |
| McNamara, PJ | 1 |
| Lapointe, A | 1 |
| Jain, A | 1 |
| Louw, J | 1 |
| Brown, S | 1 |
| Thewissen, L | 1 |
| Smits, A | 1 |
| Eyskens, B | 1 |
| Heying, R | 1 |
| Cools, B | 1 |
| Levtchenko, E | 1 |
| Allegaert, K | 1 |
| Gewillig, M | 1 |
| Hwang, W | 1 |
| Kim, E | 1 |
| Samiee-Zafarghandy, S | 1 |
| Raman, SR | 1 |
| van den Anker, JN | 1 |
| McHutchison, K | 1 |
| Clark, RH | 1 |
| Brian Smith, P | 1 |
| Meyer, S | 1 |
| Tagawa, M | 1 |
| Nanba, H | 1 |
| Suzuki, H | 1 |
| Nakamura, Y | 1 |
| Uchiyama, H | 1 |
| Ochiai, S | 1 |
| Terunuma, M | 1 |
| Yahata, K | 1 |
| Minamino, T | 1 |
| Kalish, BT | 1 |
| Cuevas Valenzuela, P | 1 |
| Rufino Ruiz, J | 1 |
| Palacios Blanco, E | 1 |
| Toth-Heyn, P | 1 |
| Cataldi, L | 1 |
| Saab, G | 1 |
| Mindel, G | 1 |
| Ewald, G | 1 |
| Vijayan, A | 1 |
| Smull, DL | 1 |
| Jorde, UP | 1 |
| Liet, JM | 1 |
| Jacqueline, C | 1 |
| Orsonneau, JL | 1 |
| Gras-Leguen, C | 1 |
| Potel, G | 1 |
| Rozé, JC | 1 |
| Seri, I | 2 |
| Noori, S | 1 |
| Osborn, DA | 1 |
| Johnston, AM | 1 |
| Carr, B | 1 |
| Jeon, Y | 1 |
| Ryu, JH | 1 |
| Lim, YJ | 1 |
| Kim, CS | 1 |
| Bahk, JH | 1 |
| Yoon, SZ | 1 |
| Choi, JY | 1 |
| Lange, M | 1 |
| Van Aken, H | 1 |
| Westphal, M | 1 |
| Mayr, V | 1 |
| Luckner, G | 1 |
| Jochberger, S | 1 |
| Wenzel, V | 1 |
| Ulmer, H | 1 |
| Pajk, W | 1 |
| Knotzer, H | 1 |
| Friesenecker, B | 1 |
| Lindner, K | 1 |
| Hasibeder, W | 1 |
| Dünser, M | 1 |
| Earl, GL | 1 |
| Verbos-Kazanas, MA | 1 |
| Fitzpatrick, JM | 1 |
| Narula, J | 1 |
| Shubert, J | 1 |
| Mancano, MA | 1 |
| Pina, IL | 1 |
| Milfred, SK | 1 |
| Mehra, MR | 1 |
| Ventura, HO | 1 |
| Kapoor, C | 1 |
| Stapleton, DD | 1 |
| Zimmerman, D | 1 |
| Smart, FW | 1 |
| Alhashemi, JA | 1 |
| Hooper, J | 1 |
| Orime, Y | 1 |
| Shiono, M | 1 |
| Hata, H | 1 |
| Yagi, S | 1 |
| Tsukamoto, S | 1 |
| Okumura, H | 1 |
| Kimura, S | 1 |
| Hata, M | 1 |
| Sezai, A | 1 |
| Obana, M | 1 |
| Sezai, Y | 1 |
| Gold, JA | 1 |
| Cullinane, S | 2 |
| Chen, J | 2 |
| Oz, MC | 2 |
| Oliver, JA | 2 |
| Landry, DW | 2 |
| Gold, J | 1 |
| Seo, S | 1 |
| Feneck, RO | 1 |
| Sherry, KM | 1 |
| Withington, PS | 1 |
| Oduro-Dominah, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Levosimendan Administration in High Risk Cardiac Surgery Patients With Pulmonary Hypertension[NCT04599816] | 45 participants (Actual) | Interventional | 2020-10-17 | Completed | |||
| Comparison of Intravenous Levosimendan and Inhalational Milrinone in High Risk Cardiac Patients With Pulmonary Hypertension[NCT04718350] | 40 participants (Anticipated) | Interventional | 2021-01-27 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
5 reviews available for milrinone and Hypotension
| Article | Year |
|---|---|
What Inotrope and Why?
Topics: Cardiac Output; Cardiotonic Agents; Dobutamine; Dopamine; Echocardiography; Epinephrine; Heart; Huma | 2020 |
The Use of Cardiotonic Drugs in Neonates.
Topics: Adrenal Cortex Hormones; Asphyxia Neonatorum; Cardiotonic Agents; Dobutamine; Dopamine; Heart Defect | 2019 |
Vasoactive compounds in the neonatal period.
Topics: Adrenal Cortex Hormones; Cardiovascular System; Catecholamines; Humans; Hydrazones; Hypotension; Inf | 2012 |
Diagnosis and treatment of neonatal hypotension outside the transitional period.
Topics: Adrenal Insufficiency; Dobutamine; Dopamine; Ductus Arteriosus, Patent; Humans; Hypotension; Infant, | 2005 |
Diagnosis and treatment of preterm transitional circulatory compromise.
Topics: Adrenal Cortex Hormones; Blood Circulation; Blood Pressure; Cardiac Output, Low; Dobutamine; Dopamin | 2005 |
4 trials available for milrinone and Hypotension
| Article | Year |
|---|---|
The effect of milrinone on induced hypotension in elderly patients during spinal surgery: a randomized controlled trial.
Topics: Aged; Blood Loss, Surgical; Double-Blind Method; Elective Surgical Procedures; Female; Hemodynamics; | 2014 |
Comparative hemodynamic effects of vasopressin and norepinephrine after milrinone-induced hypotension in off-pump coronary artery bypass surgical patients.
Topics: Aged; Coronary Artery Bypass, Off-Pump; Double-Blind Method; Female; Humans; Hypotension; Intraopera | 2006 |
Safety and clinical utility of long-term intravenous milrinone in advanced heart failure.
Topics: Adult; Aged; Cardiotonic Agents; Cohort Studies; Dobutamine; Drug Administration Schedule; Drug Ther | 1997 |
Comparison of the hemodynamic effects of milrinone with dobutamine in patients after cardiac surgery.
Topics: Adrenergic beta-Agonists; Blood Gas Analysis; Cardiac Output, Low; Cardiac Surgical Procedures; Dobu | 2001 |
25 other studies available for milrinone and Hypotension
| Article | Year |
|---|---|
The relationship between simulated milrinone exposure and hypotension in children.
Topics: Cardiotonic Agents; Child; Hemodynamics; Humans; Hypotension; Milrinone | 2022 |
Inhaled Levosimendan for Pulmonary Hypertension Treatment During Cardiac Surgery: A Novel Application to Avoid Systemic Hypotension.
Topics: Double-Blind Method; Humans; Hypertension, Pulmonary; Hypotension; Milrinone; Mitral Valve; Pilot Pr | 2019 |
Inhaled Levosimendan for Pulmonary Hypertension Treatment During Cardiac Surgery: A Novel Application to Avoid Systemic Hypotension.
Topics: Double-Blind Method; Humans; Hypertension, Pulmonary; Hypotension; Milrinone; Mitral Valve; Pilot Pr | 2019 |
Inhaled Levosimendan for Pulmonary Hypertension Treatment During Cardiac Surgery: A Novel Application to Avoid Systemic Hypotension.
Topics: Double-Blind Method; Humans; Hypertension, Pulmonary; Hypotension; Milrinone; Mitral Valve; Pilot Pr | 2019 |
Inhaled Levosimendan for Pulmonary Hypertension Treatment During Cardiac Surgery: A Novel Application to Avoid Systemic Hypotension.
Topics: Double-Blind Method; Humans; Hypertension, Pulmonary; Hypotension; Milrinone; Mitral Valve; Pilot Pr | 2019 |
Population Pharmacokinetics and Dosing of Milrinone After Patent Ductus Arteriosus Ligation in Preterm Infants.
Topics: Cardiotonic Agents; Ductus Arteriosus, Patent; Echocardiography; Female; Humans; Hypotension; Infant | 2019 |
Myocarditis in fulminant meningococcemia.
Topics: Adult; Anti-Bacterial Agents; Cardiotonic Agents; Ceftriaxone; Cerebrospinal Fluid; Confusion; Femal | 2019 |
Adrenal function in preterm infants undergoing patent ductus arteriosus ligation.
Topics: Adrenal Insufficiency; Adrenocorticotropic Hormone; Cardiotonic Agents; Cohort Studies; Ductus Arter | 2013 |
Neonatal circulatory failure due to acute hypertensive crisis: clinical and echocardiographic clues.
Topics: Acute Disease; Antihypertensive Agents; Aortic Valve Insufficiency; Arterial Pressure; Body Weight; | 2013 |
Safety of milrinone use in neonatal intensive care units.
Topics: Cardiotonic Agents; Female; Humans; Hypotension; Infant, Newborn; Infant, Premature; Intensive Care | 2015 |
Use of milrinone in neonatal intensive care medicine.
Topics: Cardiotonic Agents; Female; Humans; Hypotension; Intensive Care Units, Neonatal; Male; Milrinone; Th | 2015 |
Ventricular Rhythm and Hypotension in a Patient with Pheochromocytoma-induced Myocardial Damage and Reverse Takotsubo Cardiomyopathy.
Topics: Abdominal Pain; Adrenal Gland Neoplasms; Adrenergic beta-Antagonists; Adult; Biomarkers; Cardiac Cat | 2015 |
Dosing of Milrinone in Preterm Neonates to Prevent Postligation Cardiac Syndrome: Simulation Study Suggests Need for Bolus Infusion.
Topics: Cardiac Output; Cardiotonic Agents; Ductus Arteriosus, Patent; Estonia; Female; Gestational Age; Hum | 2017 |
Management of Neonatal Hypotension.
Topics: Blood Pressure; Cardiotonic Agents; Dobutamine; Dopamine; Ductus Arteriosus, Patent; Humans; Hypoten | 2017 |
[Mulibrey syndrome: anesthetic management].
Topics: Abnormalities, Multiple; Anesthesia, Inhalation; Ascites; Child; Comorbidity; Dopamine; Drainage; Fe | 2010 |
Acute renal failure secondary to milrinone in a patient with cardiac amyloidosis.
Topics: Acute Kidney Injury; Adrenergic beta-Agonists; Amyloidosis; Cardiotonic Agents; Dobutamine; Drug Adm | 2002 |
Concomitant use of nesiritide and milrinone in decompensated congestive heart failure.
Topics: Adult; Aged; Blood Pressure; Cardiotonic Agents; Drug Synergism; Drug Therapy, Combination; Female; | 2005 |
The effects of milrinone on hemodynamics in an experimental septic shock model.
Topics: Animals; Dilatation, Pathologic; Disease Models, Animal; Female; Hemodynamics; Hypotension; Milrinon | 2005 |
Community-acquired bacterial meningitis.
Topics: Catheterization, Swan-Ganz; Community-Acquired Infections; Humans; Hypotension; Meningitis, Bacteria | 2006 |
Is vasopressin really superior to norepinephrine in reversing milrinone-induced vasodilation?
Topics: Coronary Artery Bypass; Humans; Hypotension; Milrinone; Norepinephrine; Vasoconstrictor Agents; Vaso | 2006 |
Arginine vasopressin in advanced cardiovascular failure during the post-resuscitation phase after cardiac arrest.
Topics: Aged; Arginine Vasopressin; Bilirubin; Blood Pressure; Epinephrine; Female; Heart Arrest; Humans; Hy | 2007 |
Cardiovascular support in the preterm: treatments in search of indications.
Topics: Cardiac Output, Low; Cardiotonic Agents; Cardiovascular System; Dopamine; Female; Humans; Hypotensio | 2007 |
Tolerability of beta-blockers in outpatients with refractory heart failure who were receiving continuous milrinone.
Topics: Adrenergic beta-Antagonists; Aged; Arrhythmias, Cardiac; Blood Pressure; Carbazoles; Cardiac Output, | 2007 |
Criteria for use of intravenous milrinone in adult inpatients.
Topics: Adult; Arrhythmias, Cardiac; Cardiotonic Agents; Female; Heart Failure; Humans; Hypotension; Infusio | 1995 |
Treatment of milrinone-associated tachycardia with beta-blockers.
Topics: Adrenergic beta-Antagonists; Aged; Anesthesia, Epidural; Anesthesia, General; Anti-Arrhythmia Agents | 1998 |
Effects of phosphodiesterase inhibitors after coronary artery bypass grafting.
Topics: Aged; Cardiotonic Agents; Coronary Artery Bypass; Dobutamine; Dopamine; Female; Hemodynamics; Humans | 1999 |
Vasopressin as an alternative to norepinephrine in the treatment of milrinone-induced hypotension.
Topics: Aged; Aged, 80 and over; Cardiotonic Agents; Coronary Artery Bypass; Fatal Outcome; Female; Heart Va | 2000 |
Vasopressin in the treatment of milrinone-induced hypotension in severe heart failure.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Blood Pressure; Cyclic Nucleotide Phosphodiesterases, Type 3; H | 2000 |